

# Development of anti-VISTA antibody PMC-309 for the treatment of NSCLC

PharmAbcine Inc.



ONCOLOGY	Non-Clinical						
Product Type	Fully human monoclonal antibody (mAb)						
Indication	1st Indication: Non-Small-Cell Lung Cancer						
Target	V-domain Ig Suppressor of T cell Activation (VISTA)						
MoA(Mechanism of Action)	VISTA interaction with VISTA receptor in immuno-suppressive cells such as MDSC, is effectively disrupted by anti-VISTA antibody PMC-309 → T cell activation → Anti-cancer effect						
Competitiveness	Company Name	Drug Name	pH preference	Partner	IgG Type	Development Stage	Indication
	PharmAbcine	PMC-309	Pan pH	VSIG3 PSGL1	Fully human IgG1	IND enabling	Advanced solid tumors
	Curis	Onvatilimab (CI-8993)	Pan pH	VSIG3 PSGL1	Fully human IgG1	Phase I	Advanced solid tumors
	Hummingbird Bioscience	HMBD-002	Pan pH	VSIG3 LRIG1	Fully human IgG4	Phase I	NSCLC TNBC
	Pierre Fabre Pharmaceuticals	W0180	N/D	PSGL1	humanized IgG1	Phase I	Solid Tumors
Development Stage	Preclinical (IND-enabling)						
Route of Administration	Parenteral-Intravenous						